ZVRA - Zevra Therapeutics, Inc. Price-to-Projected Revenue Ratio

Zevra Therapeutics Inc (ZVRA) - corporate logo

Zevra Therapeutics (ZVRA) develops medications for the therapy of rare genetic brain pathologies. The company's forward P/S valuation reflects market expectations, with the current level standing at 5.30. Orphan drug status guarantees a monopoly and premium pricing power. The business relies on specialized medicine, offering breakthrough solutions for sleep and attention. Approved products generate a stable cash flow with no signs of decline.

Zevra Therapeutics Inc - ZVRA Projected Price to Revenue (period 04/28/2023 - 11/16/2026)

Financial and market metric breakdowns for Zevra Therapeutics (ZVRA)

- market price and analyst price targets:
- market capitalization statistics:
Initial company analysis:Kempharm (ZVRA)
Manufactured products of Zevra Corp

To assess long-term overpayment risks, an investor must analyze the forward P/S ratio, calculated as market capitalization divided by expected revenue. A sharp spike in this chart signals inflated expectations, which is critical for Zevra Therapeutics (ZVRA), where high asset valuations must be justified by strict FDA approval and the protection of unique patents from competitors.